GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, April 13, 2021
Time:	2:30 – 3:20 p.m. Eastern Time (ET)
Panel title:	COVID-19 Vaccines – Staying Ahead of the Curve
Novavax participant:	Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development More on Marylandian Ismail Sirdah's Guide To Landing Event Sponsorships Alex. Brown Realty & Student Quarters Acquire 440-Bed Community Near The University of Alabama Maryland: Joint Release: Invasive Fish from Conowingo Dam Donated to Food Banks, Science Maryland: UPDATE: Governor Hogan Lifts Capacity Limits on Indoor and Outdoor Venues, All Remaining Restrictions on Indoor and Outdoor Dining As of May 15 Summer Travel is Returning. Ten Tips for Safe Family Travel with Kids During COVID-19
	This event is open to Goldman Sachs clients.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

More on Marylandian

• Docent Health's Consumer Engagement Platform Powers Sutter Health's Award-Winning New Mental Health Tool for Youth
• HungMargs Craft Margarita Mix from Delray Beach's TheHungCompany To Launch at First Stop on Jimmy Buffett's Worldwide Tour
• edjuster Field Claims Team Manages Largest Catastrophic Content Claims Event in North America
• BoatBlurb.com Celebrates One Year Anniversary with Record Monthly Traffic
• 26th Annual AfroSolo Arts Festival - Black Voices: Our Stories, Our Lives - June 9-13 and 17-20, 2021

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]

Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]

Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
[email protected]

SOURCE Novavax, Inc.

Related Links

http://www.novavax.com

---

Show All News | Report Violation